Clinical outcomes and visual prognostic factors in congenital aniridia

Clinical outcomes and visual prognostic factors in congenital aniridia | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Clinical outcomes and visual prognostic factors in congenital aniridia Adam Jacobson, Shahzad I. Mian, Brenda L. Bohnsack This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1405282/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 8 You are reading this latest preprint version Abstract Background: Evaluate outcomes and identify prognostic factors in congenital aniridia. Methods : Retrospective interventional case series of patients with congenital aniridia treated between 2012-2020. Ocular examination and surgical details were collected. Surgical failure was defined as disease progression or need for additional surgery for same/related indication. Kaplan-Meier survival curves, Wilcoxon test, and univariate and multivariate linear regression analyses were performed. Results: Ninety-four patients with congenital aniridia presented at median 19.0 years. Two-thirds of patients underwent > 1intraocular surgery, with average of 1.7 ± 2.3 surgeries/eye. At final follow-up (median 4.0 years), 45% of eyes had undergone lensectomy. Aphakic eyes showed worse visual acuity (VA) than phakic or pseudophakic eyes. Glaucoma affected 52% of eyes, of which half required IOP-lowering surgery. Glaucoma drainage devices showed the highest success rate (71%) at 14.2±15.4 years of follow-up. Keratopathy affected 65% of eyes and one-third underwent corneal surgery. Keratoprosthesis had the longest survival rates at 10-years (64% with 95% CI [32,84]). LogMAR VA at presentation and final follow-up were not statistically different. Half of patients were legally blind at final follow-up. Final VA was associated with presenting VA, glaucoma diagnosis, and cataract or keratopathy at presentation. Penetrating keratoplasty and keratoprosthesis implantation correlated with worse BCVA. Conclusions: Most aniridic patients in this large US-based cohort underwent at least 1 intraocular surgery. Cataract, glaucoma, and keratopathy were associated with worse VA and are important prognostic factors to consider when managing congenital aniridia. aniridia glaucoma glaucoma drainage device keratopathy keratoplasty cataract Figures Figure 1 Figure 2 Figure 3 Figure 4 Background Despite being named for iris hypoplasia, congenital aniridia affects almost all eye structures. Optic nerve and foveal hypoplasia cause early visual impairment, while cataracts, refractory glaucoma and keratopathy result in progressive vision loss.[1 2] Congenital aniridia is typically due to autosomal dominant mutations in PAX6 .[3 4] Approximately 2/3 of cases are familial while 1/3 are sporadic. A small proportion of the sporadic cases have WAGR syndrome (OMIM194072), a 11p13 contiguous gene deletion syndrome involving PAX6 and WT1 genes.[ 5 ] Aniridia reports have focused on outcomes of one aspect, such as cataracts, glaucoma, or keratopathy.[ 6 – 13 ] Few studies, most European or Asian based, have examined the epidemiology and overall clinical outcomes.[ 14 – 17 ] In the current study, we present clinical courses and visual outcomes of one of the largest US-based cohort of aniridic patients. We aimed to determine prognostic factors that influence vision in order to help guide the care of individuals with aniridia. Methods A retrospective review identified patients with congenital aniridia at the University of Michigan from August 2012-April 2020. This study was approved by the Institutional Review Board at the University of Michigan and the research was performed in accordance with the Declaration of Helsinki. As a retrospective study, obtaining informed consent from the patients was waived by the Institutional Review Board at the University of Michigan. Collected data included age, gender, family history, ocular and systemic diagnoses, genetic mutation, and intraocular surgeries. Examination findings including initial and final best corrected visual acuity (BCVA), intraocular pressure (IOP), refractive error, slit lamp, and fundus exam findings were recorded. Optotype BCVA was converted to LogMAR format. Non-optotype vision recorded as counting fingers, hand motion, light perception, and no light perception were approximated as 1.9, 2.3, 2.7, and 3.0 LogMAR, respectively. Vision in non-verbal patients that was recorded as “central steady and maintained”, “reacts to light”, “prefers/holds”, was not incorporated in statistical testing. A change in BCVA between presentation and final follow-up was defined as a difference of > 0.1 LogMAR. Statistical analyses were performed with SPSS (IBM Corp, Armonk, NY). Univariate and multivariate linear regression was used to test for statistical significance of covariates with final LogMAR BCVA. Surgical failure was defined as further progression of the disease, the need for repeat surgery, or additional surgery for the same or related indication. A p-value of < 0.05 was considered statistically significant. Results Ninety-four patients with congenital aniridia were identified, of which 46 (49%) were male. Median age at presentation was 19.0 years (mean 23.7 ± 21.6 years, range 0–84). Self-identified racial ethnicity was Caucasian (87%), Black (9%), Asian (3%), and Hispanic (1%). Fifty-one patients (54%) had positive family history (familial) while 28 (30%) were documented to have no family history (sporadic). The remaining 15 patients (16%) did not have family history documented in the medical record. There were no differences in sex (p = 0.85), race (p = 0.85) or follow up length (p = 0.235) amongst aniridic patients classified as familial, sporadic, and unknown family history. Twelve patients were members of a previously described 4-generation family, in which genetic testing showed a splice-site mutation (c.565TC > T) in PAX6 (NM_000280.4).[ 18 ] Seven additional patients were related to this family by marriage (Fig. 1 ). Other familial relationships within our cohort included: father with 3 children, mother with 2 children, father and son, brother and sister twin siblings, and 2 sister pairs. In addition to the aforementioned splice-site mutation, 1 patient with familial aniridia had 11p14.1-p13 deletion (951Kb loss) and 1 patient had 8p23.2 duplication of unknown significance (Supplemental Table 1). Within the sporadic group, 4 patients had a confirmed mutation involving PAX6 or the neighboring ELP gene. Five patients with WAGR syndrome had gene deletions or duplications involving 11p14. Interestingly, 1 patient who clinically had WAGR syndrome had a frameshift mutation reportedly affecting PAX6 , but not adjacent genes. At median follow-up of 4.0 years (mean 8.7 ± 12.0 years, range 0.1–53.8), 112 eyes (60%) of 62 patients (66%) underwent at least 1 surgery. Of these patients, 12 had unilateral surgery while 50 had bilateral surgeries. The average number of surgeries was 1.74 ± 2.30/eye (median 1, range 0–14). At presentation, the crystalline lens was present in 125 eyes (66%) of 66 patients (70%), of which 79 of 125 (63%) had cataract (Fig. 2 A). Forty-nine eyes (26%) of 31 patients(33%) had previously undergone lensectomy, with 30 eyes (59%) having intraocular lens (IOL) implantation and 19 eyes (37%) remaining aphakic. Three eyes (2%) of 3 patients (3%) had enucleations prior to presentation and 9 eyes (5%) of 7 patients (7%) had unknown lens status due to corneal opacification. At final follow-up, 91 eyes (48%) of 52 patients (55%) remained phakic, although 61 eyes had a cataract and 3 eyes showed partial lens dislocation. Thus, an additional 36 eyes underwent lensectomy such that at final follow-up 85 eyes (45%) of 51 patients (54%) were pseudophakic and 30 eyes (16%) of 20 patients (21%) were aphakic. Only 1 eye had capsular tension ring (CTR) placement during lensectomy. Four eyes of 3 patients initially had IOL placement, which was later removed due to dislocation. Two additional eyes were enucleated during follow-up. Seven eyes (4%) of 6 patients (6%) had corneal opacification that precluded lens status at final follow-up. At presentation, 75 eyes (40%) of 39 patients (41%) had glaucoma, of which 17 eyes (23%) of 12 patients (31%) had undergone prior IOP-lowering surgery (Fig. 2 B). At final follow-up, 98 eyes (52%) of 50 patients (53%) had glaucoma, of which 49 eyes of 28 patients required IOP-lowering surgery with an average of 1.9 ± 1.6 surgeries/eye (range 1–10, median 1). Due to the extensive length of follow-up and conversion from paper to electronic records, accurate survival times were unable to be calculated for 54 of 94 glaucoma surgeries performed. Survival times of less than half of the surgeries would not yield accurate results, however, success rates at final follow-up were determined (Table 1 ). Success at final follow-up of Baerveldt and Ahmed GDDs were 74% and 63%, respectively. This increased to 87% and 88% if failure criteria did not include tube revision. Success of trabeculectomy with anti-fibrotics was 24%, which increased to 33% if bleb revision surgeries were excluded. Angle surgery showed 33% success. Success of cycloablation was 33% which increased to 50% if multiple cycloablations were excluded. There was no significant difference in length of follow-up between glaucoma surgeries (p > 0.2). Table 1 Glaucoma Surgery Glaucoma Surgery (n) Previous Glaucoma Surgeries 0 1 >2 surgeries surgery surgeries Success at Final Follow-up Success Exclusion Success with Exclusion at Final Follow-up Length of Follow-up (yrs) Glaucoma Drainage Device (35) Baerveldt (23) Ahmed (8) Unspecified (4) 23 eyes 7 eyes 5 eyes 16 eyes 4 eyes 3 eyes 3 eyes 3 eyes 2 eyes 4 eyes 71% (25 of 35 Eyes) 74% (17 of 23 Eyes) 63% (5 of 8 Eyes) 75% (3 of 4 Eyes) Tube Revision 89% (31 of 35 Eyes) 87% (20 of 23 Eyes) 88% (7 of 8 Eyes) 100% (4 of 4 Eyes) 14.2 ± 15.4 13.2 ± 14.3 17.5 ± 20.1 2.7 ± 3.6 Trabeculectomy with Anti-Fibrotics (21) 14 eyes 6 eyes 1 eye 24% (5 of 21 Eyes) Bleb Revision 33% (7 of 14 Eyes) 21.7 ± 14.1 Angle Surgery (9) Trabeculotomy (5) Goniotomy (4) 8 eyes 1 eye 4 eyes 1 eye 4 eyes 33% (3 of 9 Eyes) 40% (2 of 5 Eyes) 25% (1 of 4 Eyes) Repeat Angle Surgery 33% (3 of 9 Eyes) 40% (2 of 5 Eyes) 25% (1 of 4 Eyes) 16.3 ± 17.8 26.6 ± 15.3 0.9 ± 1.3 Cycloablation (12) Contact Transcleral (5) Endoscopic (6) Cryo (1) 3 eyes 4 eyes 5 eyes 1 eye 1 eye 3 eyes 2 eyes 3 eyes 1 eye 1 eye 33% (4 of 12 Eyes) 40% (2 of 5 Eyes) 17% (1 of 6 Eyes) 100% (1 of 1 Eye) Multiple Cyclo- Ablations 50% (6 of 12 Eyes) 60% (3 of 5 Eyes) 33% (2 of 6 Eyes) 100% (1 of 1 Eye) 23.4 ± 12.0 19.8 ± 7.4 20.5 ± 8.6 43.4 At presentation, 108 eyes(57%) of 56 patients(60%) had keratopathy, including 1 eye which had already undergone Boston keratoprosthesis (KPro) implantation (Fig. 2 C). At final follow-up, 123 eyes (65%) of 63 patients (67%) had keratopathy, of which 44 eyes (36%) of 28 patients (44%) underwent at least 1 corneal procedure. The average number of corneal surgeries was 1.7 ± 1.1/eye (range 1–6, median 1). Corneal surgeries included penetrating keratoplasty (PKP, 19 eyes), Kpro (18 eyes), limbal stem cell transplantation (LSCT, 12 eyes), lamellar keratoplasty (LK, 4 eyes), and Descemet stripping endothelial keratoplasty (DSEK, 3 eyes). Kaplan-Meier analysis showed that PKP (Fig. 3 A) had 1, 10, and 25-year survival rates of 90% with 95% CI [71, 96], 43% with 95% CI [23, 62], and 20% with 95% CI [6, 40], respectively. Of the 18 eyes which underwent KPro, 11 had not undergone prior corneal surgery while 6 had a history of failed PKP and 1 had previous LK. KPro survival rates were 95% with 95% CI [70, 99] at 1-year, 83% with 95% CI [55, 94] at 5-years, and 64% with 95% CI [32, 84] at 10-years. DSEK (Fig. 3 B) 1-year survival rate was 75% with 95% CI [13, 96] and decreased to 25% with 95% CI [1, 66] at 2 years. LK had 5-year, 10-year, and 15-year survival rates of 88% with 95% CI [40, 99], 63% with 95% CI [23, 87], and 31% with 95% CI [6, 64], respectively. LSCT showed a 1-year survival rate of 75% with 95% CI [13, 96] and 5-year survival rate of 25% with 95% CI [1, 66]. Log-rank (Mantel Cox) analysis showed a significant difference between survival curves of the aforementioned corneal surgeries (p = 0.0006). Additional surgeries included pars plana vitrectomy (PPV) in 20 eyes (11%) and artificial iris implantation in 4 eyes (2%). In 13 eyes, PPV was performed in conjunction with GDD implantation (7 eyes) and/or KPro placement (6 eyes). Two additional eyes had PPV combined with trabeculectomy or PKP. Five eyes underwent PPV to repair retinal detachments that were due to prior surgery (3 eyes), trauma (1 eye) or an optic nerve pit (1 eye). One eye, in addition to PPV, also had placement of scleral buckle for a KPro-related retinal detachment. LogMAR BCVA at presentation (1.46 ± 0.46, median 1.0) was not significantly different (p = 0.51) than at final follow-up (1.32 ± 0.76, median 1.10). At final follow-up, 57 eyes (30%) had BCVA better than 20/200 with 11 (6%) having BCVA of 20/50 or better (Fig. 4 A). In contrast, 107 eyes (57%) had BCVA worse than 20/200 with 16 eyes (9%) with no light perception. Twenty-four eyes (13%) were too young to cooperate with optotype testing at final follow-up. Analysis of the better seeing eye in each patient (Fig. 4 B) showed similar results with 38% with BCVA better than 20/200. However, 50% met the legal definition of blindness in the better seeing eye at final follow-up. Optotype visual acuity testing was completed at both initial and final visits in 133 eyes (71%) of 67 patients (71%). Ninety-three eyes (50%) had stable (< 0.1 change in LogMar VA) or improved BCVA (Fig. 4 C) while 40 eyes (21%) showed worse BCVA at final follow-up. Likewise, BCVA of the better seeing eye (Fig. 4 D) improved or remained stable in 52% of patients, but decreased in 19% of patients. Univariate analysis of all 188 eyes showed that final BCVA was associated with BCVA at initial presentation (p < 0.001), age at initial presentation (p < 0.0001), glaucoma diagnosis (p < 0.001), cataract at presentation (p = 0.037), and presence of keratopathy at presentation (p < 0.0001). While there was no difference in final BCVA between phakic and pseudophakic eyes, aphakic eyes showed worse BCVA compared to pseudophakic (p < 0.005) and phakic (p < 0.005) eyes. Furthermore, eyes which underwent PKP or KPro implantation were associated with worse BCVA (p < 0.0001 and p < 0.05, respectively). There was no relationship between final BCVA and LSCT, glaucoma surgery, retina surgery, or iris prosthetic implantation. Neither sex nor race were associated with final BCVA. No variables modified sex or race in order to predict worse final BCVA. Discussion Congenital aniridia involves almost all ocular structures, and therefore affects vision via numerous mechanisms.[1 2] This study presents the clinical courses and visual outcomes in the largest US-based cohort of aniridic patients to date and aims to improve prognostication and management of this disease. Cataracts are common in aniridia with rates of 40–80%.[ 1 15 – 17 ] Lens extraction in aniridia presents unique challenges including altered anterior chamber dynamics, abnormal capsule and zonule properties, and corneal opacification.[11 19] This coupled with the decreased viability of the sulcus as an alternative location for an IOL, makes lensectomy complicated. There are few studies on outcomes of cataract surgery in aniridia.[11 19] One Chinese study with 17 eyes of 10 patients showed improvement in vision and decrease in photophobia after cataract surgery with CTR and IOL placement.[ 11 ] In our study, 68% of individuals at presentation either were noted to have a cataract or had already undergone lens extraction and this increased to 80% at final follow-up. The presence of cataract at presentation was associated with worse BCVA at final follow-up. This is in contrast to a Korean study in which cataract at initial or final visit was not associated with visual outcome.[ 1 ] However, Chang et al focused on the pediatric population, with 85% of their cohort being younger than 3 years. Furthermore, there were fewer patients (60), a lower rate of cataract formation (53%), and ultimately only 25% of the eyes underwent lensectomy. In our study, 85 eyes (45%) underwent cataract surgery, and the 30 eyes which were aphakic had worse outcomes compared to pseudophakic and phakic eyes. Additional factors, such as amblyopia and contact lens intolerance, may further compromise visual function in aphakic individuals. Glaucoma affects at least 50% of individuals with aniridia. [20 21] The mechanisms underlying increased IOP include iridogoniodysgenesis and iris stump anterior rotation leading to angle closure. We found that glaucoma was associated with worse visual outcomes. Further, Jain et al showed that higher baseline IOP and multiple glaucoma surgeries were associated with worse visual outcomes.[ 22 ] Angle surgery, and namely goniotomy, has been advocated as a prophylactic measure to lower the iris root to decrease its anterior rotation.[20 21] Since this would need to be done prior to glaucoma onset and has the risk of lens and cornea damage, this has largely fallen out of favor. In aniridic eyes with elevated IOP, angle surgery has a success rate that ranges from 0–80% with trabeculotomy more successful than goniotomy. However, these reports are hampered by limited follow-up and few patients.[20 21 23] In the current study, angle surgery was not performed prophylactically, but only in eyes with elevated IOP. At final follow-up, one-third of eyes which underwent angle surgery remained successful, which is a much lower rate compared to other childhood glaucomas.[24 25] Thus, while trabeculotomy and goniotomy can be performed in aniridic glaucoma, it behooves the surgeon to prepare the patient for subsequent IOP-lowering surgeries. Trabeculectomy also has limited success in aniridia. In Wiggins and Tomey, trabeculectomy in 17 eyes had a success rate of 9%.[ 6 ] More recently, an Indian study showed 42% success rate of trabeculectomy with mitomycin C at 2-years in 12 eyes.[ 26 ] In our study, we found a 33% success rate in 21 eyes. Because of low success and life-long infection risk, GDDs have supplanted trabeculectomy for many surgeons. In 3 small cohorts, Ahmed GDDs showed a 67–87% survival rate at 1-year, and Baerveldts had 88% success with less than 3 years of follow-up [9 12 27] In our study, Baerveldt devices in 23 eyes showed 74% success while Ahmeds in 8 eyes had 63% success at final follow-up which ranged between 0.5–22 years. These studies suggest that GDDs are more successful than trabeculectomy and angle surgery in obtaining IOP-control in aniridia. Nonetheless, it is important to note specific considerations with GDDs in aniridia. Intraoperative placement is difficult due to shallow anterior chambers and minimal lens protection. Furthermore, the combination of iris hypoplasia and limbal stem cell deficiency dictates careful placement of the tube such that it minimizes contact with both the lens and corneal endothelium. Keratopathy is present in up to 80% of individuals with aniridia.[28 29] Early scarring may be treated medically or by superficial keratectomy with amniotic membrane grafting. LSCT is an option in moderate keratopathy. Prior studies show a greater than 70% success of LSCT with improvement in vision.[ 30 ] However, allogenic and not autologous stem cells must be transplanted, which typically necessitates systemic immunosuppression.[ 30 ] In the current study, LSCT showed poor success with complete failure in all eyes after 5 years. This may be due to keratopathy severity and follow-up length. With severe scarring, corneal transplantation is typically the next step. PKP and partial thickness grafts both show high failure rates in aniridia due to limbal stem cell deficiency and endothelial dysfunction.[ 31 ] In our cohort, DSEK had 25% survival at 2-years, while LK and PKP had similarly low survival rates after 15-years such that many eventually ended up with a KPros. While previous studies have shown modest success of KPros implants, there are long-term complications such as glaucoma, retinal detachment, extrusion, endophthalmitis, and phthisis. [8 10 13 32] In our cohort, KPros showed the highest rates of survival at 5 and 10-years compared to other corneal surgeries, but given this relatively new technology, length of follow-up in these eyes was shorter than other surgeries. It is important to note that our study showed that PKP and KPro implantation were associated with worse BCVA at final follow-up. Although both procedures are prone to failure in aniridia, it is likely that the corneal opacification, which was the original indication was already severely limiting vision. Thus, realistic expectations regarding potential complications and likelihood of additional surgeries must be set with aniridic patients undergoing corneal transplantation or keratoprosthesis surgery. The strengths of our study are the large number of eyes and patients and the long length of follow-up. Limitations include the retrospective nature of the case series, variable time of follow-up, and variable disease severity at initial presentation. In addition, the intraocular surgeries (cataract, glaucoma, and cornea) were performed by multiple surgeons who had different criteria for intervention and various surgical techniques. There also may have been changes in surgical techniques over the duration of follow-up making comparison between surgical success difficult. In conclusion, congenital aniridia is a complex disease with multiple mechanisms that underlie both early and progressive vision loss. Treatment is life long and requires a good understanding of the risks unique to aniridia. In this large US-based cohort of patients with congenital aniridia, we found that most patients underwent at least 1 eye surgery and that cataract, glaucoma, and keratopathy were associated with worse BCVA at final follow-up. This study helps determine important prognostic factors and guide treatments that will yield the best visual outcomes in congenital aniridia. Conclusions In this large US-based cohort, the majority of patients with congenital aniridia underwent at least 1 intraocular surgery. At least half of patients developed glaucoma and keratopathy. Cataract, glaucoma, and keratopathy were associated with worse visual acuity. Abbreviations VA Visual Acuity BCVA Best Corrected Visual Acuity IOP Intraocular Pressure Declarations Ethics approval and consent to participate: This research was performed in accordance with the Declaration of Helsinki. As a retrospective study, this study was approved as exempt and obtaining informed consent from the patients was waived by the Institutional Review Board at the University of Michigan. Consent for publication: Not applicable Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author (BLB). Competing Interests: The authors have no competing interests. Funding: None Authors’ Contributions: Research design (AJ, SIM, BLB), Data collection and analysis (AJ, BLB), Manuscript preparation and final approval (AJ, SIM, BLB) Acknowledgements: None References Chang JW, Kim JH, Kim S-J, Yu YS. Congenital aniridia: Long-term clinical course, visual outcome, and pronostic factors. Korean J Ophthalmol 2014; 28 (6):479-85 Samant M, Chauhan BK, Lathrop KL, Nischal KK. Congenital aniridia: Etiology, manifestations and management. Expert Rev Ophthalmol 2016; 11 (2):135-44 Calvão-Pires P, Santos-Silva R, Falcão-Reis F, Rocha-Sousa A. Congenital aniridia: Clinic, genetics, therapeutics, and prognosis. Int Sch Res Notices 2014; 2014 :305350 Wawrocka A, Krawczynski MR. The genetics of aniridia - simple things become complicated. J Appl Genet 2018; 59 (2):151-59 Hingorani M, Hanson I, van Heyningen V. Aniridia. Eur J Hum Genet 2012; 20 :1011-17 Wiggins RE, Tomey KF. The results of glaucoma surgery in aniridia. Arch Ophthalmol 1992; 110 :503-05 Mayer KL, Nordlund ML, Schwartz GS, Holland EJ. Keratopathy in congenital aniridia. Ocul Surf 2003; 1 (2):74-79 Rixen JJ, Cohen AW, Kitzmann AS, Wagoner MD, Goins KM. Treatment of aniridia with Boston Type 1 Keratoprosthesis. Cornea 2013; 32 (7):947-50 Almousa R, Lake DB. Intraocular pressure control with Ahmed glaucoma drainage device in patients with cicatricial ocular surface disease-associated or aniridia-related glaucoma. Int Ophthalmol 2014; 34 :753-60 Hassanaly SI, Talajic JC, Harissi-Dagher M. Outcomes following Boston Type 1 Keratoprosthesis implantation in aniridia patients at the University of Montreal. Am J Ophthalmol 2014; 158 :270-76 Wang JD, Zhang JS, Xiong Y, et al. Congenital aniridia with cataract: case series. BMC Ophthalmol 2017; 17 :115 Demirok GS, Eksioglu U, Yakin M, Kaderli A, Kaderli ST, Onek F. Short- and long-term results of glaucoma valve implantation for aniridia-related glaucoma: A case series and literature review. Turk J Ophthalmol 2019; 49 :183-87 Nascimento E Silva R, Shen LQ, Chiou CA, et al. Glaucoma management in patients with aniridia and Boston Type 1 Keratoprosthesis. Am J Ophthalmol 2019; 207 :258-67 Lee H, Meyers K, Lanigan B, O’Keefe M. Complications and visual prognosis in children with aniridia. J Pediatr Ophthalmol Strabismus 2010; 47 (4):205-10 Park SH, Park YG, Lee MY, Kim MS. Clinical features of Korean patients with congenital aniridia. Korean J Ophthalmol 2010; 24 (5):291-96 Netland PA, Scott ML, Boyle JW, Lauderdale JD. Ocular and systemic findings in a survey of aniridia subjects. J AAPOS 2011; 15 :562-66 Singh B, Mohamed A, Chaurasia S, et al. Clinical manifestations of congenital aniridia. J Pediatr Ophthalmol Strabismus 2014; 51 (1):59-62 Wang GM, Prasov L, Al-Hasani H, et al. Phenotypic variation in a four-generation family with aniridia carrying a novel PAX6 mutation. J Ophthalmol 2018; 2018 :5978293 Neuhann IM, Neuhann TF. Cataract surgery and aniridia. Curr Opin Ophthalmol 2010; 21 (1):60-64 Chen TC, Walton DS. Goniosurgery for prevention of aniridic glaucoma. Arch Ophthalmol 1999; 117 (9):1144-48 Swanner JC, Walton DS, Chen TC. Prevention of aniridic glaucoma with goniosurgery. Int Ophthalmol Clin 2004; 44 (1):67-71 Jain A, Gupta S, James MK, Dutta P, Gupta V. Aniridic glaucoma: Long-term visual outcomes and phenotypic associations. J Glaucoma 2015; 24 (7):539-42 Adachi M, Dickens CJ, Hetherington JJ, et al. Clinical experience of trabeculotomy for the surgical treatment of aniridic glaucoma. Ophthalmology 1997; 104 (12):2121-25 Wallace DK, Plager DA, Snyder SK, Raiesdana A, Helveston EM, Ellis FD. Surgical results of secondary glaucomas in childhood. Ophthalmology 1998; 105 :101-11 Taylor RH, Ainsworth JR, Evans AR, Levin AV. The epidemiology of pediatric glaucoma: the Toronto experience. J AAPOS 1999; 3 (5):308-15 Durai I, Pallamparthy S, Puthuran GV, et al. Outcomes of glaucoma drainage device implantation and trabeculectomy with mitomycin C in glaucoma secondary to aniridia. Am J Ophthalmol 2021; 227 :173-81 Arroyave CP, Scott IU, Gedde SJ, Parrish RK, Feuer WJ. Use of glaucoma drainage devices in the management of glaucoma associated with aniridia. Am J Ophthalmol 2002; 135 :155-59 Lee H, Khan R, O’Keefe M. Aniridia: current pathology and management. Acta Ophthalmol 2008; 86 (7):708-15 Lee HJ, Colby KA. A review of the clinical and genetic aspects of aniridia. Semin Ophthalmol 2013; 28 (5-6):306-12 Holland EJ, Djalilian AR, Schwartz GS. Management of aniridic keratopathy with keratolimbal allograft: a limbal stem cell transplantation technique. Ophthalmology 2003; 110 (1):125-30 Kremer I, Rajpal RK, Rapuano CJ, Cohen EJ, Laibson PR. Results of penetrating keratoplasty in aniridia. Am J Ophthalmol 1993; 115 (3):317-20 Yazdanpanah G, Bohm KJ, Hassan OM, et al. Management of congenital aniridia-associated keratopathy: Long-term outcomes from a tertiary referral center. Am J Ophthalmol 2020; 210 :8-18 Additional Declarations No competing interests reported. Supplementary Files SupplementalTableGenetics01122022.pdf Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Major revision 28 Mar, 2022 Reviews received at journal 22 Mar, 2022 Reviewers agreed at journal 14 Mar, 2022 Reviewers invited by journal 12 Mar, 2022 Editor assigned by journal 07 Mar, 2022 Editor invited by journal 07 Mar, 2022 Submission checks completed at journal 07 Mar, 2022 First submitted to journal 28 Feb, 2022 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1405282","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":88750432,"identity":"bf3c5da7-47a9-45fb-a31c-4c40150f7b0d","order_by":0,"name":"Adam Jacobson","email":"","orcid":"","institution":"Michigan Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Adam","middleName":"","lastName":"Jacobson","suffix":""},{"id":88750433,"identity":"537e4abb-2d9f-4726-b5e0-3d88234ba491","order_by":1,"name":"Shahzad I. Mian","email":"","orcid":"","institution":"Michigan Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Shahzad","middleName":"I.","lastName":"Mian","suffix":""},{"id":88750434,"identity":"a4a1bcca-6899-414b-b75b-a69a016e01d5","order_by":2,"name":"Brenda L. Bohnsack","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABD0lEQVRIiWNgGAWjYBACAwkGNjBDgr25AcgFImbmBgnitPAchGlhJFaLRGIDRISBgBZz6eZjjwv+2MlLznzYJl1RYCNvzs7YeLui4o49A3vv4xdYtFjOOZZuPLMt2XC2dGKb5BmDNMOdzYzNlmfOPEts4DluZoHNYTdyzKR5G5gT5EBaGgwOJxgcZmyTbGw7nMAgkcZmgEsLz5/6BDnJgyAt/6Fa/h22x6+F7XCCtAQjSMsBqJaGw8BASGN+gN0vadK8bccNZ/YkNls2GCQbbjgM9EvDscOJbTzH2HCFGNBh1fISxw8fvNkADDqD8yBGzWF7fvY25g/YwxkXAFrBhjeCsAJSbRkFo2AUjILhCQA3XWGHy43WLgAAAABJRU5ErkJggg==","orcid":"","institution":"Lurie Children's Hospital","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Brenda","middleName":"L.","lastName":"Bohnsack","suffix":""}],"badges":[],"createdAt":"2022-02-28 18:44:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1405282/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1405282/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":19040125,"identity":"713ecde5-fef6-43b1-9aed-c8471a36b22e","added_by":"auto","created_at":"2022-03-09 19:27:05","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":137565,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePedigree of 4-Generation Family with Aniridia\u003c/strong\u003e\u003c/p\u003e\u003cp\u003ePedigree of 4 generation family that includes 19 individuals with aniridia. Seven members have a previously reported \u003cem\u003ePAX6 \u003c/em\u003e(NM_000280.4) c.565TC\u0026gt;T frame shift mutation that results in a premature stop codon. An additional seven individuals with aniridia were related by marriage in the second generation.\u0026nbsp;\u003c/p\u003e","description":"","filename":"OnlineFigure101112022.png","url":"https://assets-eu.researchsquare.com/files/rs-1405282/v1/8c2e99a7675c11b34c644554.png"},{"id":19040126,"identity":"eaf9d969-95c0-41c4-aee6-94abb4f75ebd","added_by":"auto","created_at":"2022-03-09 19:27:05","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":449608,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eProportion of Aniridic Individuals with Cataract, Glaucoma and Keratopathy\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eA)\u0026nbsp;At presentation, 66% of aniridic eyes were phakic while 26% had undergone cataract surgery and were either pseudophakic (16%) or aphakic (10%). The remaining eyes were either enucleated (2%) or the lens status was unknown (5%) due to corneal opacification. At final follow-up, 48% of the eyes were phakic, 29% were pseudophakic, 16% were aphakic, 3% were enucleated and 4% had unknown status due to corneal pacification. \u003c/p\u003e\u003cp\u003eB)\u0026nbsp;Forty percent of eyes had a diagnosis of glaucoma at presentation and 9% had already undergone at least 1 IOP-lowering surgery. Glaucoma diagnosis increased to 52% at final follow-up and 26% of eyes required glaucoma surgery. \u003c/p\u003e\u003cp\u003eC)\u0026nbsp;At presentation, 57% of aniridic eye had keratopathy and 0.5% had undergone corneal surgery. At final follow-up, the percent of eyes with keratopathy increased to 65% and 23% had at least 1 corneal surgery.\u0026nbsp;\u003c/p\u003e","description":"","filename":"OnlineFigure201112022.png","url":"https://assets-eu.researchsquare.com/files/rs-1405282/v1/84a92cf6d45af50d2d838875.png"},{"id":19040127,"identity":"1a2b62a9-5b9a-417e-a1cf-4caab2f5a45a","added_by":"auto","created_at":"2022-03-09 19:27:05","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":212102,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSurvival Curves of Corneal Surgery in Aniridia\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eA)\u0026nbsp;Kaplan-Meier survival rates of penetrating keratoplasty (PKP) were 90% with 95% CI [71, 96] at 1-year, 43% with 95% CI [23, 62] at 10-years, and 20% with 95% CI [6, 40] at 25-years. Keratoprosthesis (KPro) survival rate at 1-year, 5-years, and 10-years was 95% with 95% CI [70, 99] and 83% with 95% CI [55, 94] at 5-years, and 64% with 95% CI [32, 84], respectively\u003cem\u003e. \u003c/em\u003e\u003c/p\u003e\u003cp\u003eB)\u0026nbsp;Survival rates of limbal stem cell transplantation (LSCT) were 75% with 95% CI [13, 96] at 1-year and 25% with 95% CI [1, 66] at 5-years. Descemet stripping and endothelial keratoplasty (DSEK) 1-year survival rate was 75% with 95% CI [13, 96] and decreased to 25% with 95% CI [1, 66] at 2 years. Five-year, 10-year, and 15-year survival rates of lamellar keratoplasty (LK) were 88% with 95% CI [40, 99], 63% with 95% CI [23, 87], and 31% with 95% CI [6, 64], respectively.\u003c/p\u003e","description":"","filename":"OnlineFigure301112022.png","url":"https://assets-eu.researchsquare.com/files/rs-1405282/v1/6c5aab7fe7622faa44e2ab21.png"},{"id":19040128,"identity":"97c0f50c-1b92-410c-9978-3f6966eb69c2","added_by":"auto","created_at":"2022-03-09 19:27:05","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":437080,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVisual Acuity Outcomes \u003c/strong\u003e\u003c/p\u003e\u003cp\u003eA)\u0026nbsp;At final follow-up of the 188 eyes, 30% of eyes had LogMAR VA \u003cu\u003e\u0026lt;\u003c/u\u003e 0.9 (BCVA better than 20/200) and 6% had LogMAR VA \u003cu\u003e\u0026lt;\u003c/u\u003e 0.4 (BCVA 20/50 or better). Fifty-seven percent of eyes had LogMAR VA \u003cu\u003e\u0026gt;\u003c/u\u003e 1.0 (BCVA 20/200 or worse) with 9% unable to detect light. Thirteen percent of patients were too young to cooperate with optotype testing. \u003c/p\u003e\u003cp\u003eB)\u0026nbsp;Analysis of the better seeing eye showed that 50% of the patients met the legal definition of blindness with LogMAR VA \u003cu\u003e\u0026gt;\u003c/u\u003e 1.0 (20/200 or worse) at final follow-up. One percent of patients were not able to detect light with either eye. Thirty-eight percent of patients had LogMAR VA \u003cu\u003e\u0026lt;\u003c/u\u003e 0.9 (better than 20/200) and 9% of patients had LogMAR VA \u003cu\u003e\u0026lt;\u003c/u\u003e 0.4 (20/50 or better). \u003c/p\u003e\u003cp\u003eC)\u0026nbsp;In the 133 of 188 eyes that were able to complete optotype visual acuity testing at both initial and final visits, 34% of eyes showed stable VA (\u0026lt;0.1 change in LogMAR VA) and 16% of eyes had an improvement in VA. Twenty-one percent of eyes showed worse LogMAR VA at final follow-up. Twenty-nine percent of patients lacked optotypte testing at either presentation or final follow-up. \u003c/p\u003e\u003cp\u003eD)\u0026nbsp;\u0026nbsp;Analysis of the better seeing eye showed that 35% of patients had stable VA (\u0026lt; 0.1 change in LogMAR VA) at initial and final follow-up. Seventeen percent of patients had improved LogMAR VA while 19% had worse VA at final follow-up compared to presentation.\u0026nbsp;\u003c/p\u003e","description":"","filename":"OnlineFigure4VA01112022.png","url":"https://assets-eu.researchsquare.com/files/rs-1405282/v1/e2a63e4bbdfff921217ed423.png"},{"id":19041401,"identity":"01844a03-6118-44c9-819c-b65323f75348","added_by":"auto","created_at":"2022-03-09 19:30:08","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":482357,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1405282/v1/aafa216b-358c-491e-b69f-c548e4a36ba7.pdf"},{"id":19041400,"identity":"38188c76-62bb-4404-8d95-15c5fb9e90a8","added_by":"auto","created_at":"2022-03-09 19:30:05","extension":"pdf","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":83943,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalTableGenetics01122022.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1405282/v1/cc58fa572d7b7aea5483c6e5.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Clinical outcomes and visual prognostic factors in congenital aniridia","fulltext":[{"header":"Background","content":"\u003cp\u003eDespite being named for iris hypoplasia, congenital aniridia affects almost all eye structures. Optic nerve and foveal hypoplasia cause early visual impairment, while cataracts, refractory glaucoma and keratopathy result in progressive vision loss.[1 2] Congenital aniridia is typically due to autosomal dominant mutations in \u003cem\u003ePAX6\u003c/em\u003e.[3 4] Approximately 2/3 of cases are familial while 1/3 are sporadic. A small proportion of the sporadic cases have WAGR syndrome (OMIM194072), a 11p13 contiguous gene deletion syndrome involving \u003cem\u003ePAX6\u003c/em\u003e and \u003cem\u003eWT1\u003c/em\u003e genes.[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eAniridia reports have focused on outcomes of one aspect, such as cataracts, glaucoma, or keratopathy.[\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10 CR11 CR12\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] Few studies, most European or Asian based, have examined the epidemiology and overall clinical outcomes.[\u003cspan additionalcitationids=\"CR15 CR16\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e] In the current study, we present clinical courses and visual outcomes of one of the largest US-based cohort of aniridic patients. We aimed to determine prognostic factors that influence vision in order to help guide the care of individuals with aniridia.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e A retrospective review identified patients with congenital aniridia at the University of Michigan from August 2012-April 2020. This study was approved by the Institutional Review Board at the University of Michigan and the research was performed in accordance with the Declaration of Helsinki. As a retrospective study, obtaining informed consent from the patients was waived by the Institutional Review Board at the University of Michigan. Collected data included age, gender, family history, ocular and systemic diagnoses, genetic mutation, and intraocular surgeries. Examination findings including initial and final best corrected visual acuity (BCVA), intraocular pressure (IOP), refractive error, slit lamp, and fundus exam findings were recorded.\u003c/p\u003e \u003cp\u003eOptotype BCVA was converted to LogMAR format. Non-optotype vision recorded as counting fingers, hand motion, light perception, and no light perception were approximated as 1.9, 2.3, 2.7, and 3.0 LogMAR, respectively. Vision in non-verbal patients that was recorded as \u0026ldquo;central steady and maintained\u0026rdquo;, \u0026ldquo;reacts to light\u0026rdquo;, \u0026ldquo;prefers/holds\u0026rdquo;, was not incorporated in statistical testing. A change in BCVA between presentation and final follow-up was defined as a difference of \u0026gt;\u0026thinsp;0.1 LogMAR.\u003c/p\u003e \u003cp\u003eStatistical analyses were performed with SPSS (IBM Corp, Armonk, NY). Univariate and multivariate linear regression was used to test for statistical significance of covariates with final LogMAR BCVA. Surgical failure was defined as further progression of the disease, the need for repeat surgery, or additional surgery for the same or related indication. A p-value of \u0026lt;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eNinety-four patients with congenital aniridia were identified, of which 46 (49%) were male. Median age at presentation was 19.0 years (mean 23.7\u0026thinsp;\u0026plusmn;\u0026thinsp;21.6 years, range 0\u0026ndash;84). Self-identified racial ethnicity was Caucasian (87%), Black (9%), Asian (3%), and Hispanic (1%). Fifty-one patients (54%) had positive family history (familial) while 28 (30%) were documented to have no family history (sporadic). The remaining 15 patients (16%) did not have family history documented in the medical record. There were no differences in sex (p\u0026thinsp;=\u0026thinsp;0.85), race (p\u0026thinsp;=\u0026thinsp;0.85) or follow up length (p\u0026thinsp;=\u0026thinsp;0.235) amongst aniridic patients classified as familial, sporadic, and unknown family history.\u003c/p\u003e \u003cp\u003eTwelve patients were members of a previously described 4-generation family, in which genetic testing showed a splice-site mutation (c.565TC\u0026thinsp;\u0026gt;\u0026thinsp;T) in \u003cem\u003ePAX6\u003c/em\u003e (NM_000280.4).[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e] Seven additional patients were related to this family by marriage (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Other familial relationships within our cohort included: father with 3 children, mother with 2 children, father and son, brother and sister twin siblings, and 2 sister pairs. In addition to the aforementioned splice-site mutation, 1 patient with familial aniridia had 11p14.1-p13 deletion (951Kb loss) and 1 patient had 8p23.2 duplication of unknown significance (Supplemental Table\u0026nbsp;1). Within the sporadic group, 4 patients had a confirmed mutation involving \u003cem\u003ePAX6\u003c/em\u003e or the neighboring \u003cem\u003eELP\u003c/em\u003e gene. Five patients with WAGR syndrome had gene deletions or duplications involving 11p14. Interestingly, 1 patient who clinically had WAGR syndrome had a frameshift mutation reportedly affecting \u003cem\u003ePAX6\u003c/em\u003e, but not adjacent genes.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAt median follow-up of 4.0 years (mean 8.7\u0026thinsp;\u0026plusmn;\u0026thinsp;12.0 years, range 0.1\u0026ndash;53.8), 112 eyes (60%) of 62 patients (66%) underwent at least 1 surgery. Of these patients, 12 had unilateral surgery while 50 had bilateral surgeries. The average number of surgeries was 1.74\u0026thinsp;\u0026plusmn;\u0026thinsp;2.30/eye (median 1, range 0\u0026ndash;14). At presentation, the crystalline lens was present in 125 eyes (66%) of 66 patients (70%), of which 79 of 125 (63%) had cataract (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). Forty-nine eyes (26%) of 31 patients(33%) had previously undergone lensectomy, with 30 eyes (59%) having intraocular lens (IOL) implantation and 19 eyes (37%) remaining aphakic. Three eyes (2%) of 3 patients (3%) had enucleations prior to presentation and 9 eyes (5%) of 7 patients (7%) had unknown lens status due to corneal opacification. At final follow-up, 91 eyes (48%) of 52 patients (55%) remained phakic, although 61 eyes had a cataract and 3 eyes showed partial lens dislocation. Thus, an additional 36 eyes underwent lensectomy such that at final follow-up 85 eyes (45%) of 51 patients (54%) were pseudophakic and 30 eyes (16%) of 20 patients (21%) were aphakic. Only 1 eye had capsular tension ring (CTR) placement during lensectomy. Four eyes of 3 patients initially had IOL placement, which was later removed due to dislocation. Two additional eyes were enucleated during follow-up. Seven eyes (4%) of 6 patients (6%) had corneal opacification that precluded lens status at final follow-up.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAt presentation, 75 eyes (40%) of 39 patients (41%) had glaucoma, of which 17 eyes (23%) of 12 patients (31%) had undergone prior IOP-lowering surgery (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). At final follow-up, 98 eyes (52%) of 50 patients (53%) had glaucoma, of which 49 eyes of 28 patients required IOP-lowering surgery with an average of 1.9\u0026thinsp;\u0026plusmn;\u0026thinsp;1.6 surgeries/eye (range 1\u0026ndash;10, median 1). Due to the extensive length of follow-up and conversion from paper to electronic records, accurate survival times were unable to be calculated for 54 of 94 glaucoma surgeries performed. Survival times of less than half of the surgeries would not yield accurate results, however, success rates at final follow-up were determined (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Success at final follow-up of Baerveldt and Ahmed GDDs were 74% and 63%, respectively. This increased to 87% and 88% if failure criteria did not include tube revision. Success of trabeculectomy with anti-fibrotics was 24%, which increased to 33% if bleb revision surgeries were excluded. Angle surgery showed 33% success. Success of cycloablation was 33% which increased to 50% if multiple cycloablations were excluded. There was no significant difference in length of follow-up between glaucoma surgeries (p\u0026thinsp;\u0026gt;\u0026thinsp;0.2).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eGlaucoma Surgery\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGlaucoma Surgery (n)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrevious Glaucoma Surgeries\u003c/p\u003e \u003cp\u003e0 1 \u0026gt;2\u003c/p\u003e \u003cp\u003esurgeries surgery surgeries\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSuccess at Final Follow-up\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSuccess Exclusion\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSuccess with \u003c/p\u003e \u003cp\u003eExclusion at Final Follow-up\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eLength of \u003c/p\u003e \u003cp\u003eFollow-up (yrs)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eGlaucoma Drainage Device (35)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eBaerveldt (23)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eAhmed (8)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eUnspecified (4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23 eyes 7 eyes 5 eyes\u003c/p\u003e \u003cp\u003e16 eyes 4 eyes 3 eyes\u003c/p\u003e \u003cp\u003e3 eyes 3 eyes 2 eyes\u003c/p\u003e \u003cp\u003e4 eyes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e71% (25 of 35 Eyes)\u003c/p\u003e \u003cp\u003e74% (17 of 23 Eyes)\u003c/p\u003e \u003cp\u003e63% (5 of 8 Eyes)\u003c/p\u003e \u003cp\u003e75% (3 of 4 Eyes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eTube \u003c/p\u003e \u003cp\u003eRevision\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e89% (31 of 35 Eyes)\u003c/p\u003e \u003cp\u003e87% (20 of 23 Eyes)\u003c/p\u003e \u003cp\u003e88% (7 of 8 Eyes)\u003c/p\u003e \u003cp\u003e100% (4 of 4 Eyes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e14.2\u0026thinsp;\u0026plusmn;\u0026thinsp;15.4\u003c/p\u003e \u003cp\u003e13.2\u0026thinsp;\u0026plusmn;\u0026thinsp;14.3\u003c/p\u003e \u003cp\u003e17.5\u0026thinsp;\u0026plusmn;\u0026thinsp;20.1\u003c/p\u003e \u003cp\u003e2.7\u0026thinsp;\u0026plusmn;\u0026thinsp;3.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTrabeculectomy with Anti-Fibrotics (21)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14 eyes 6 eyes 1 eye\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24% (5 of 21 Eyes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBleb \u003c/p\u003e \u003cp\u003eRevision\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33% (7 of 14 Eyes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c6\"\u003e \u003cp\u003e21.7\u0026thinsp;\u0026plusmn;\u0026thinsp;14.1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAngle Surgery (9)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eTrabeculotomy (5)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eGoniotomy (4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8 eyes 1 eye\u003c/p\u003e \u003cp\u003e4 eyes 1 eye\u003c/p\u003e \u003cp\u003e4 eyes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33% (3 of 9 Eyes)\u003c/p\u003e \u003cp\u003e40% (2 of 5 Eyes)\u003c/p\u003e \u003cp\u003e25% (1 of 4 Eyes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRepeat \u003c/p\u003e \u003cp\u003eAngle Surgery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33% (3 of 9 Eyes)\u003c/p\u003e \u003cp\u003e40% (2 of 5 Eyes)\u003c/p\u003e \u003cp\u003e25% (1 of 4 Eyes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c6\"\u003e \u003cp\u003e16.3\u0026thinsp;\u0026plusmn;\u0026thinsp;17.8\u003c/p\u003e \u003cp\u003e26.6\u0026thinsp;\u0026plusmn;\u0026thinsp;15.3\u003c/p\u003e \u003cp\u003e0.9\u0026thinsp;\u0026plusmn;\u0026thinsp;1.3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCycloablation (12)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eContact Transcleral (5)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eEndoscopic (6)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eCryo (1)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 eyes 4 eyes 5 eyes\u003c/p\u003e \u003cp\u003e1 eye 1 eye 3 eyes\u003c/p\u003e \u003cp\u003e2 eyes 3 eyes 1 eye\u003c/p\u003e \u003cp\u003e1 eye\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33% (4 of 12 Eyes)\u003c/p\u003e \u003cp\u003e40% (2 of 5 Eyes)\u003c/p\u003e \u003cp\u003e17% (1 of 6 Eyes)\u003c/p\u003e \u003cp\u003e100% (1 of 1 Eye)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMultiple Cyclo-\u003c/p\u003e \u003cp\u003eAblations\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50% (6 of 12 Eyes)\u003c/p\u003e \u003cp\u003e60% (3 of 5 Eyes)\u003c/p\u003e \u003cp\u003e33% (2 of 6 Eyes)\u003c/p\u003e \u003cp\u003e100% (1 of 1 Eye)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c6\"\u003e \u003cp\u003e23.4\u0026thinsp;\u0026plusmn;\u0026thinsp;12.0\u003c/p\u003e \u003cp\u003e19.8\u0026thinsp;\u0026plusmn;\u0026thinsp;7.4\u003c/p\u003e \u003cp\u003e20.5\u0026thinsp;\u0026plusmn;\u0026thinsp;8.6\u003c/p\u003e \u003cp\u003e43.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAt presentation, 108 eyes(57%) of 56 patients(60%) had keratopathy, including 1 eye which had already undergone Boston keratoprosthesis (KPro) implantation (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). At final follow-up, 123 eyes (65%) of 63 patients (67%) had keratopathy, of which 44 eyes (36%) of 28 patients (44%) underwent at least 1 corneal procedure. The average number of corneal surgeries was 1.7\u0026thinsp;\u0026plusmn;\u0026thinsp;1.1/eye (range 1\u0026ndash;6, median 1). Corneal surgeries included penetrating keratoplasty (PKP, 19 eyes), Kpro (18 eyes), limbal stem cell transplantation (LSCT, 12 eyes), lamellar keratoplasty (LK, 4 eyes), and Descemet stripping endothelial keratoplasty (DSEK, 3 eyes). Kaplan-Meier analysis showed that PKP (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA) had 1, 10, and 25-year survival rates of 90% with 95% CI [71, 96], 43% with 95% CI [23, 62], and 20% with 95% CI [6, 40], respectively. Of the 18 eyes which underwent KPro, 11 had not undergone prior corneal surgery while 6 had a history of failed PKP and 1 had previous LK. KPro survival rates were 95% with 95% CI [70, 99] at 1-year, 83% with 95% CI [55, 94] at 5-years, and 64% with 95% CI [32, 84] at 10-years. DSEK (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB) 1-year survival rate was 75% with 95% CI [13, 96] and decreased to 25% with 95% CI [1, 66] at 2 years. LK had 5-year, 10-year, and 15-year survival rates of 88% with 95% CI [40, 99], 63% with 95% CI [23, 87], and 31% with 95% CI [6, 64], respectively. LSCT showed a 1-year survival rate of 75% with 95% CI [13, 96] and 5-year survival rate of 25% with 95% CI [1, 66]. Log-rank (Mantel Cox) analysis showed a significant difference between survival curves of the aforementioned corneal surgeries (p\u0026thinsp;=\u0026thinsp;0.0006).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAdditional surgeries included pars plana vitrectomy (PPV) in 20 eyes (11%) and artificial iris implantation in 4 eyes (2%). In 13 eyes, PPV was performed in conjunction with GDD implantation (7 eyes) and/or KPro placement (6 eyes). Two additional eyes had PPV combined with trabeculectomy or PKP. Five eyes underwent PPV to repair retinal detachments that were due to prior surgery (3 eyes), trauma (1 eye) or an optic nerve pit (1 eye). One eye, in addition to PPV, also had placement of scleral buckle for a KPro-related retinal detachment.\u003c/p\u003e \u003cp\u003eLogMAR BCVA at presentation (1.46\u0026thinsp;\u0026plusmn;\u0026thinsp;0.46, median 1.0) was not significantly different (p\u0026thinsp;=\u0026thinsp;0.51) than at final follow-up (1.32\u0026thinsp;\u0026plusmn;\u0026thinsp;0.76, median 1.10). At final follow-up, 57 eyes (30%) had BCVA better than 20/200 with 11 (6%) having BCVA of 20/50 or better (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). In contrast, 107 eyes (57%) had BCVA worse than 20/200 with 16 eyes (9%) with no light perception. Twenty-four eyes (13%) were too young to cooperate with optotype testing at final follow-up. Analysis of the better seeing eye in each patient (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB) showed similar results with 38% with BCVA better than 20/200. However, 50% met the legal definition of blindness in the better seeing eye at final follow-up. Optotype visual acuity testing was completed at both initial and final visits in 133 eyes (71%) of 67 patients (71%). Ninety-three eyes (50%) had stable (\u0026lt;\u0026thinsp;0.1 change in LogMar VA) or improved BCVA (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC) while 40 eyes (21%) showed worse BCVA at final follow-up. Likewise, BCVA of the better seeing eye (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD) improved or remained stable in 52% of patients, but decreased in 19% of patients.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eUnivariate analysis of all 188 eyes showed that final BCVA was associated with BCVA at initial presentation (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), age at initial presentation (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001), glaucoma diagnosis (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), cataract at presentation (p\u0026thinsp;=\u0026thinsp;0.037), and presence of keratopathy at presentation (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). While there was no difference in final BCVA between phakic and pseudophakic eyes, aphakic eyes showed worse BCVA compared to pseudophakic (p\u0026thinsp;\u0026lt;\u0026thinsp;0.005) and phakic (p\u0026thinsp;\u0026lt;\u0026thinsp;0.005) eyes. Furthermore, eyes which underwent PKP or KPro implantation were associated with worse BCVA (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and p\u0026thinsp;\u0026lt;\u0026thinsp;0.05, respectively). There was no relationship between final BCVA and LSCT, glaucoma surgery, retina surgery, or iris prosthetic implantation. Neither sex nor race were associated with final BCVA. No variables modified sex or race in order to predict worse final BCVA.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eCongenital aniridia involves almost all ocular structures, and therefore affects vision via numerous mechanisms.[1 2] This study presents the clinical courses and visual outcomes in the largest US-based cohort of aniridic patients to date and aims to improve prognostication and management of this disease.\u003c/p\u003e \u003cp\u003eCataracts are common in aniridia with rates of 40\u0026ndash;80%.[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e \u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e] Lens extraction in aniridia presents unique challenges including altered anterior chamber dynamics, abnormal capsule and zonule properties, and corneal opacification.[11 19] This coupled with the decreased viability of the sulcus as an alternative location for an IOL, makes lensectomy complicated. There are few studies on outcomes of cataract surgery in aniridia.[11 19] One Chinese study with 17 eyes of 10 patients showed improvement in vision and decrease in photophobia after cataract surgery with CTR and IOL placement.[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] In our study, 68% of individuals at presentation either were noted to have a cataract or had already undergone lens extraction and this increased to 80% at final follow-up. The presence of cataract at presentation was associated with worse BCVA at final follow-up. This is in contrast to a Korean study in which cataract at initial or final visit was not associated with visual outcome.[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] However, Chang et al focused on the pediatric population, with 85% of their cohort being younger than 3 years. Furthermore, there were fewer patients (60), a lower rate of cataract formation (53%), and ultimately only 25% of the eyes underwent lensectomy. In our study, 85 eyes (45%) underwent cataract surgery, and the 30 eyes which were aphakic had worse outcomes compared to pseudophakic and phakic eyes. Additional factors, such as amblyopia and contact lens intolerance, may further compromise visual function in aphakic individuals.\u003c/p\u003e \u003cp\u003eGlaucoma affects at least 50% of individuals with aniridia. [20 21] The mechanisms underlying increased IOP include iridogoniodysgenesis and iris stump anterior rotation leading to angle closure. We found that glaucoma was associated with worse visual outcomes. Further, Jain et al showed that higher baseline IOP and multiple glaucoma surgeries were associated with worse visual outcomes.[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e] Angle surgery, and namely goniotomy, has been advocated as a prophylactic measure to lower the iris root to decrease its anterior rotation.[20 21] Since this would need to be done prior to glaucoma onset and has the risk of lens and cornea damage, this has largely fallen out of favor. In aniridic eyes with elevated IOP, angle surgery has a success rate that ranges from 0\u0026ndash;80% with trabeculotomy more successful than goniotomy. However, these reports are hampered by limited follow-up and few patients.[20 21 23] In the current study, angle surgery was not performed prophylactically, but only in eyes with elevated IOP. At final follow-up, one-third of eyes which underwent angle surgery remained successful, which is a much lower rate compared to other childhood glaucomas.[24 25] Thus, while trabeculotomy and goniotomy can be performed in aniridic glaucoma, it behooves the surgeon to prepare the patient for subsequent IOP-lowering surgeries.\u003c/p\u003e \u003cp\u003eTrabeculectomy also has limited success in aniridia. In Wiggins and Tomey, trabeculectomy in 17 eyes had a success rate of 9%.[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e] More recently, an Indian study showed 42% success rate of trabeculectomy with mitomycin C at 2-years in 12 eyes.[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e] In our study, we found a 33% success rate in 21 eyes. Because of low success and life-long infection risk, GDDs have supplanted trabeculectomy for many surgeons. In 3 small cohorts, Ahmed GDDs showed a 67\u0026ndash;87% survival rate at 1-year, and Baerveldts had 88% success with less than 3 years of follow-up [9 12 27] In our study, Baerveldt devices in 23 eyes showed 74% success while Ahmeds in 8 eyes had 63% success at final follow-up which ranged between 0.5\u0026ndash;22 years. These studies suggest that GDDs are more successful than trabeculectomy and angle surgery in obtaining IOP-control in aniridia. Nonetheless, it is important to note specific considerations with GDDs in aniridia. Intraoperative placement is difficult due to shallow anterior chambers and minimal lens protection. Furthermore, the combination of iris hypoplasia and limbal stem cell deficiency dictates careful placement of the tube such that it minimizes contact with both the lens and corneal endothelium.\u003c/p\u003e \u003cp\u003eKeratopathy is present in up to 80% of individuals with aniridia.[28 29] Early scarring may be treated medically or by superficial keratectomy with amniotic membrane grafting. LSCT is an option in moderate keratopathy. Prior studies show a greater than 70% success of LSCT with improvement in vision.[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] However, allogenic and not autologous stem cells must be transplanted, which typically necessitates systemic immunosuppression.[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] In the current study, LSCT showed poor success with complete failure in all eyes after 5 years. This may be due to keratopathy severity and follow-up length. With severe scarring, corneal transplantation is typically the next step. PKP and partial thickness grafts both show high failure rates in aniridia due to limbal stem cell deficiency and endothelial dysfunction.[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] In our cohort, DSEK had 25% survival at 2-years, while LK and PKP had similarly low survival rates after 15-years such that many eventually ended up with a KPros.\u003c/p\u003e \u003cp\u003eWhile previous studies have shown modest success of KPros implants, there are long-term complications such as glaucoma, retinal detachment, extrusion, endophthalmitis, and phthisis. [8 10 13 32] In our cohort, KPros showed the highest rates of survival at 5 and 10-years compared to other corneal surgeries, but given this relatively new technology, length of follow-up in these eyes was shorter than other surgeries. It is important to note that our study showed that PKP and KPro implantation were associated with worse BCVA at final follow-up. Although both procedures are prone to failure in aniridia, it is likely that the corneal opacification, which was the original indication was already severely limiting vision. Thus, realistic expectations regarding potential complications and likelihood of additional surgeries must be set with aniridic patients undergoing corneal transplantation or keratoprosthesis surgery.\u003c/p\u003e \u003cp\u003eThe strengths of our study are the large number of eyes and patients and the long length of follow-up. Limitations include the retrospective nature of the case series, variable time of follow-up, and variable disease severity at initial presentation. In addition, the intraocular surgeries (cataract, glaucoma, and cornea) were performed by multiple surgeons who had different criteria for intervention and various surgical techniques. There also may have been changes in surgical techniques over the duration of follow-up making comparison between surgical success difficult.\u003c/p\u003e \u003cp\u003eIn conclusion, congenital aniridia is a complex disease with multiple mechanisms that underlie both early and progressive vision loss. Treatment is life long and requires a good understanding of the risks unique to aniridia. In this large US-based cohort of patients with congenital aniridia, we found that most patients underwent at least 1 eye surgery and that cataract, glaucoma, and keratopathy were associated with worse BCVA at final follow-up. This study helps determine important prognostic factors and guide treatments that will yield the best visual outcomes in congenital aniridia.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn this large US-based cohort, the majority of patients with congenital aniridia underwent at least 1 intraocular surgery. At least half of patients developed glaucoma and keratopathy. Cataract, glaucoma, and keratopathy were associated with worse visual acuity.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eVA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eVisual Acuity\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eBCVA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eBest Corrected Visual Acuity\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIOP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eIntraocular Pressure\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003eEthics approval and consent to participate: This research was performed in accordance with the Declaration of Helsinki. As a retrospective study, this study was approved as exempt and obtaining informed consent from the patients was waived by the Institutional Review Board at the University of Michigan.\u003c/p\u003e\n\u003cp\u003eConsent for publication: Not applicable\u003c/p\u003e\n\u003cp\u003eAvailability of data and materials: The datasets used and/or analyzed during the current study are \u0026nbsp;available from the corresponding author (BLB).\u003c/p\u003e\n\u003cp\u003eCompeting Interests: The authors have no competing interests.\u003c/p\u003e\n\u003cp\u003eFunding: None\u003c/p\u003e\n\u003cp\u003eAuthors\u0026rsquo; Contributions: Research design (AJ, SIM, BLB), Data collection and analysis (AJ, BLB), \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Manuscript preparation and final approval (AJ, SIM, BLB)\u003c/p\u003e\n\u003cp\u003eAcknowledgements: None\u0026nbsp;\u003cbr\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eChang JW, Kim JH, Kim S-J, Yu YS. Congenital aniridia: Long-term clinical course, visual outcome, and pronostic factors. Korean J Ophthalmol 2014;\u003cstrong\u003e28\u003c/strong\u003e(6):479-85\u003c/li\u003e\n\u003cli\u003eSamant M, Chauhan BK, Lathrop KL, Nischal KK. Congenital aniridia: Etiology, manifestations and management. Expert Rev Ophthalmol 2016;\u003cstrong\u003e11\u003c/strong\u003e(2):135-44\u003c/li\u003e\n\u003cli\u003eCalv\u0026atilde;o-Pires P, Santos-Silva R, Falc\u0026atilde;o-Reis F, Rocha-Sousa A. Congenital aniridia: Clinic, genetics, therapeutics, and prognosis. Int Sch Res Notices 2014;\u003cstrong\u003e2014\u003c/strong\u003e:305350\u003c/li\u003e\n\u003cli\u003eWawrocka A, Krawczynski MR. The genetics of aniridia - simple things become complicated. J Appl Genet 2018;\u003cstrong\u003e59\u003c/strong\u003e(2):151-59\u003c/li\u003e\n\u003cli\u003eHingorani M, Hanson I, van Heyningen V. Aniridia. Eur J Hum Genet 2012;\u003cstrong\u003e20\u003c/strong\u003e:1011-17\u003c/li\u003e\n\u003cli\u003eWiggins RE, Tomey KF. The results of glaucoma surgery in aniridia. Arch Ophthalmol 1992;\u003cstrong\u003e110\u003c/strong\u003e:503-05\u003c/li\u003e\n\u003cli\u003eMayer KL, Nordlund ML, Schwartz GS, Holland EJ. Keratopathy in congenital aniridia. Ocul Surf 2003;\u003cstrong\u003e1\u003c/strong\u003e(2):74-79\u003c/li\u003e\n\u003cli\u003eRixen JJ, Cohen AW, Kitzmann AS, Wagoner MD, Goins KM. Treatment of aniridia with Boston Type 1 Keratoprosthesis. Cornea 2013;\u003cstrong\u003e32\u003c/strong\u003e(7):947-50\u003c/li\u003e\n\u003cli\u003eAlmousa R, Lake DB. Intraocular pressure control with Ahmed glaucoma drainage device in patients with cicatricial ocular surface disease-associated or aniridia-related glaucoma. Int Ophthalmol 2014;\u003cstrong\u003e34\u003c/strong\u003e:753-60\u003c/li\u003e\n\u003cli\u003eHassanaly SI, Talajic JC, Harissi-Dagher M. Outcomes following Boston Type 1 Keratoprosthesis implantation in aniridia patients at the University of Montreal. Am J Ophthalmol 2014;\u003cstrong\u003e158\u003c/strong\u003e:270-76\u003c/li\u003e\n\u003cli\u003eWang JD, Zhang JS, Xiong Y, et al. Congenital aniridia with cataract: case series. BMC Ophthalmol 2017;\u003cstrong\u003e17\u003c/strong\u003e:115\u003c/li\u003e\n\u003cli\u003eDemirok GS, Eksioglu U, Yakin M, Kaderli A, Kaderli ST, Onek F. Short- and long-term results of glaucoma valve implantation for aniridia-related glaucoma: A case series and literature review. Turk J Ophthalmol 2019;\u003cstrong\u003e49\u003c/strong\u003e:183-87\u003c/li\u003e\n\u003cli\u003eNascimento E Silva R, Shen LQ, Chiou CA, et al. Glaucoma management in patients with aniridia and Boston Type 1 Keratoprosthesis. Am J Ophthalmol 2019;\u003cstrong\u003e207\u003c/strong\u003e:258-67\u003c/li\u003e\n\u003cli\u003eLee H, Meyers K, Lanigan B, O\u0026rsquo;Keefe M. Complications and visual prognosis in children with aniridia. J Pediatr Ophthalmol Strabismus 2010;\u003cstrong\u003e47\u003c/strong\u003e(4):205-10\u003c/li\u003e\n\u003cli\u003ePark SH, Park YG, Lee MY, Kim MS. Clinical features of Korean patients with congenital aniridia. Korean J Ophthalmol 2010;\u003cstrong\u003e24\u003c/strong\u003e(5):291-96\u003c/li\u003e\n\u003cli\u003eNetland PA, Scott ML, Boyle JW, Lauderdale JD. Ocular and systemic findings in a survey of aniridia subjects. J AAPOS 2011;\u003cstrong\u003e15\u003c/strong\u003e:562-66\u003c/li\u003e\n\u003cli\u003eSingh B, Mohamed A, Chaurasia S, et al. Clinical manifestations of congenital aniridia. J Pediatr Ophthalmol Strabismus 2014;\u003cstrong\u003e51\u003c/strong\u003e(1):59-62\u003c/li\u003e\n\u003cli\u003eWang GM, Prasov L, Al-Hasani H, et al. Phenotypic variation in a four-generation family with aniridia carrying a novel PAX6 mutation. J Ophthalmol 2018;\u003cstrong\u003e2018\u003c/strong\u003e:5978293\u003c/li\u003e\n\u003cli\u003eNeuhann IM, Neuhann TF. Cataract surgery and aniridia. Curr Opin Ophthalmol 2010;\u003cstrong\u003e21\u003c/strong\u003e(1):60-64\u003c/li\u003e\n\u003cli\u003eChen TC, Walton DS. Goniosurgery for prevention of aniridic glaucoma. Arch Ophthalmol 1999;\u003cstrong\u003e117\u003c/strong\u003e(9):1144-48\u003c/li\u003e\n\u003cli\u003eSwanner JC, Walton DS, Chen TC. Prevention of aniridic glaucoma with goniosurgery. Int Ophthalmol Clin 2004;\u003cstrong\u003e44\u003c/strong\u003e(1):67-71\u003c/li\u003e\n\u003cli\u003eJain A, Gupta S, James MK, Dutta P, Gupta V. Aniridic glaucoma: Long-term visual outcomes and phenotypic associations. J Glaucoma 2015;\u003cstrong\u003e24\u003c/strong\u003e(7):539-42\u003c/li\u003e\n\u003cli\u003eAdachi M, Dickens CJ, Hetherington JJ, et al. Clinical experience of trabeculotomy for the surgical treatment of aniridic glaucoma. Ophthalmology 1997;\u003cstrong\u003e104\u003c/strong\u003e(12):2121-25\u003c/li\u003e\n\u003cli\u003eWallace DK, Plager DA, Snyder SK, Raiesdana A, Helveston EM, Ellis FD. Surgical results of secondary glaucomas in childhood. Ophthalmology 1998;\u003cstrong\u003e105\u003c/strong\u003e:101-11\u003c/li\u003e\n\u003cli\u003eTaylor RH, Ainsworth JR, Evans AR, Levin AV. The epidemiology of pediatric glaucoma: the Toronto experience. J AAPOS 1999;\u003cstrong\u003e3\u003c/strong\u003e(5):308-15\u003c/li\u003e\n\u003cli\u003eDurai I, Pallamparthy S, Puthuran GV, et al. Outcomes of glaucoma drainage device implantation and trabeculectomy with mitomycin C in glaucoma secondary to aniridia. Am J Ophthalmol 2021;\u003cstrong\u003e227\u003c/strong\u003e:173-81\u003c/li\u003e\n\u003cli\u003eArroyave CP, Scott IU, Gedde SJ, Parrish RK, Feuer WJ. Use of glaucoma drainage devices in the management of glaucoma associated with aniridia. Am J Ophthalmol 2002;\u003cstrong\u003e135\u003c/strong\u003e:155-59\u003c/li\u003e\n\u003cli\u003eLee H, Khan R, O\u0026rsquo;Keefe M. Aniridia: current pathology and management. Acta Ophthalmol 2008;\u003cstrong\u003e86\u003c/strong\u003e(7):708-15\u003c/li\u003e\n\u003cli\u003eLee HJ, Colby KA. A review of the clinical and genetic aspects of aniridia. Semin Ophthalmol 2013;\u003cstrong\u003e28\u003c/strong\u003e(5-6):306-12\u003c/li\u003e\n\u003cli\u003eHolland EJ, Djalilian AR, Schwartz GS. Management of aniridic keratopathy with keratolimbal allograft: a limbal stem cell transplantation technique. Ophthalmology 2003;\u003cstrong\u003e110\u003c/strong\u003e(1):125-30\u003c/li\u003e\n\u003cli\u003eKremer I, Rajpal RK, Rapuano CJ, Cohen EJ, Laibson PR. Results of penetrating keratoplasty in aniridia. Am J Ophthalmol 1993;\u003cstrong\u003e115\u003c/strong\u003e(3):317-20\u003c/li\u003e\n\u003cli\u003eYazdanpanah G, Bohm KJ, Hassan OM, et al. Management of congenital aniridia-associated keratopathy: Long-term outcomes from a tertiary referral center. Am J Ophthalmol 2020;\u003cstrong\u003e210\u003c/strong\u003e:8-18\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-ophthalmology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"boph","sideBox":"Learn more about [BMC Ophthalmology](http://bmcophthalmol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/boph","title":"BMC Ophthalmology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"aniridia, glaucoma, glaucoma drainage device, keratopathy, keratoplasty, cataract","lastPublishedDoi":"10.21203/rs.3.rs-1405282/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1405282/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground: \u003c/strong\u003eEvaluate outcomes and identify prognostic factors in congenital aniridia. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: Retrospective interventional case series of patients with congenital aniridia treated between 2012-2020. Ocular examination and surgical details were collected. Surgical failure was defined as disease progression or need for additional surgery for same/related indication. Kaplan-Meier survival curves, Wilcoxon test, and univariate and multivariate linear regression analyses were performed. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eNinety-four patients with congenital aniridia presented at median 19.0 years. Two-thirds of patients underwent \u003cu\u003e\u0026gt;\u003c/u\u003e 1intraocular surgery, with average of 1.7 ± 2.3 surgeries/eye. At final follow-up (median 4.0 years), 45% of eyes had undergone lensectomy. Aphakic eyes showed worse visual acuity (VA) than phakic or pseudophakic eyes. Glaucoma affected 52% of eyes, of which half required IOP-lowering surgery. Glaucoma drainage devices showed the highest success rate (71%) at 14.2±15.4 years of follow-up. Keratopathy affected 65% of eyes and one-third underwent corneal surgery. Keratoprosthesis had the longest survival rates at 10-years (64% with 95% CI [32,84]). LogMAR VA at presentation and final follow-up were not statistically different. Half of patients were legally blind at final follow-up. Final VA was associated with presenting VA, glaucoma diagnosis, and cataract or keratopathy at presentation. Penetrating keratoplasty and keratoprosthesis implantation correlated with worse BCVA. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusions: \u003c/strong\u003eMost aniridic patients in this large US-based cohort underwent at least 1 intraocular surgery. Cataract, glaucoma, and keratopathy were associated with worse VA and are important prognostic factors to consider when managing congenital aniridia.\u003c/p\u003e","manuscriptTitle":"Clinical outcomes and visual prognostic factors in congenital aniridia","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-03-09 19:27:03","doi":"10.21203/rs.3.rs-1405282/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major revision","date":"2022-03-28T09:21:06+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2022-03-22T15:04:45+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"a142ceb9-7281-448b-8122-f3fd11c4a927_SNPRID","date":"2022-03-14T11:17:05+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2022-03-12T17:19:27+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2022-03-07T17:07:27+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2022-03-07T08:13:49+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2022-03-07T08:09:33+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Ophthalmology","date":"2022-02-28T18:34:43+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-ophthalmology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"boph","sideBox":"Learn more about [BMC Ophthalmology](http://bmcophthalmol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/boph","title":"BMC Ophthalmology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"38c2808f-7126-46a3-8c64-3c9896d4c225","owner":[],"postedDate":"March 9th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2022-05-18T06:29:10+00:00","versionOfRecord":[],"versionCreatedAt":"2022-03-09 19:27:03","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1405282","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1405282","identity":"rs-1405282","version":["v1"]},"buildId":"WrCJVZZCHTDjtuVLN7oU0","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}